NCT00861016View on ClinicalTrials.gov

Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

May 31, 2006

Conditions
Hypertension
Interventions
DRUG

metoprolol succinate prolonged-release tablet and felodipine

a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY